awmsg logo



doxorubicin (Caelyx®)


Reference No. 114

Publication date:
03/08/2009


Appraisal information

doxorubicin (Caelyx®) 2 mg/ml concentrate for solution for infusion


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ministerial ratification: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Doxorubicin (Caelyx®) has not been endorsed for use within NHS Wales in combination with bortezomib for the treatment of progressive multiple myeloma. The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of doxorubicin (Caelyx®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.
Statement of Advice (SOA)
Download